Description:

E5103 Hematology/Chemistry Form Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer NCT00433511 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=3AE26832-8814-18AE-E044-0003BA3F9857

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=3AE26832-8814-18AE-E044-0003BA3F9857

Keywords:
Versions (5) ▾
  1. 8/26/12
  2. 1/8/15
  3. 1/9/15
  4. 1/9/15
  5. 3/27/15
Uploaded on:

March 27, 2015

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Breast Cancer Hematology/Chemistry NCT00433511

Details

INSTRUCTIONS: Complete this form and submit original to the ECOG Coordinating Center within one week of registration. Keep a copy for your files

Header
Pre-registration Hematology/chemistry
On Treatment Report Period
15 more items in the detailed view.
Were hematology/chemistry results obtained this report period (cycle)?
1000/uL
1000/uL
mmol/L
Units
CTC AE Attribution Code (Leave attribution box blank if no adverse event.)
Action taken for this AE for Chemotherapy
Back to the top of the page 

Similar models